Cyclin D1 Antikörper

Produktnummer ABIN7127907

Produktdetails anti-Cyclin D1 Antikörper

Target: Cyclin D1 (CCND1)

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser Cyclin D1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Immunoprecipitation (IP), Immunocytochemistry (ICC)

Kreuzreaktivität: Human, Maus, Ratte

Aufreinigung: Affinity purification

Immunogen: A synthetic peptide of Human Cyclin D1

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB:1:500-1:1000, IHC:1:50-1:100, ICC:1:50-1:100, IP:1:20-1:50,

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Store at -20 °C or -80 °C. Avoid freeze / thaw cycles. Buffer: PBS with 0.02 % sodium azide, 50 % glycerol, pH 7.3.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Details zu Cyclin D1

Target: Cyclin D1 (CCND1)

Andere Bezeichnung: CCND1 (CCND1 Produkte)

Synonyme: BCL1 antikoerper, D11S287E antikoerper, PRAD1 antikoerper, U21B31 antikoerper, AI327039 antikoerper, CycD1 antikoerper, Cyl-1 antikoerper, bcl-1 antikoerper, cD1 antikoerper, cb161 antikoerper, cycd1 antikoerper, etID37810.7 antikoerper, fb52e01 antikoerper, fc45c08 antikoerper, fc83a12 antikoerper, id:ibd1198 antikoerper, wu:fb52e01 antikoerper, wu:fc45c08 antikoerper, wu:fc83a12 antikoerper, ccnd1b antikoerper, prad1 antikoerper, ccnd1 antikoerper, ccnd1a antikoerper, bcl1 antikoerper, d11s287e antikoerper, u21b31 antikoerper, CCND1 antikoerper, cyclin D1 antikoerper, cyclin D1 S homeolog antikoerper, cyclin D1 L homeolog antikoerper, CCND1 antikoerper, Ccnd1 antikoerper, ccnd1 antikoerper, ccnd1.S antikoerper, ccnd1.L antikoerper

Hintergrund:

Background: Activity of the cyclin-dependent kinases CDK4 and CDK6 is regulated by T-loop phosphorylation, by the abundance of their cyclin partners (the D-type cyclins), and by association with CDK inhibitors of the Cip/Kip or INK family of proteins. The inactive ternary complex of cyclin D/CDK4 and p27 Kip1 requires extracellular mitogenic stimuli for the release and degradation of p27 concomitant with a rise in cyclin D levels to effect progression through the restriction point and pRb-dependent entry into S-phase. The active complex of cyclin D/CDK4 targets the retinoblastoma protein for phosphorylation, allowing the release of E2F transcription factors that activate G1/S-phase gene expression. Levels of cyclin D protein drop upon withdrawal of growth factors through downregulation of its protein expression and through phosphorylation-dependent degradation.

Aliases: AI327039 antibody, B cell CLL/lymphoma 1 antibody, B cell leukemia 1 antibody, B cell lymphoma 1 protein antibody, B-cell lymphoma 1 protein antibody, BCL 1 antibody, BCL-1 antibody, BCL-1 oncogene antibody, BCL1 antibody, BCL1 oncogene antibody, ccnd1 antibody, CCND1/FSTL3 fusion gene antibody, CCND1/FSTL3 fusion gene, included antibody, CCND1/IGHG1 fusion gene antibody, CCND1/IGHG1 fusion gene, included antibody, CCND1/IGLC1 fusion gene antibody, CCND1/IGLC1 fusion gene, included antibody, CCND1/PTH fusion gene antibody, CCND1/PTH fusion gene, included antibody, CCND1_HUMAN antibody, cD1 antibody, Cyl 1 antibody, D11S287E antibody, G1/S specific cyclin D1 antibody, G1/S-specific cyclin-D1 antibody, Parathyroid adenomatosis 1 antibody, PRAD1 antibody, PRAD1 oncogene antibody, U21B31 antibody

UniProt: P24385

Pathways: PI3K-Akt Signalweg, Zellzyklus, Mitotic G1-G1/S Phases, ER-Nucleus Signaling